Ocugen to Participate in Upcoming September Investor and Industry Conferences
Ocugen, Inc., a US-based biotechnology company specializing in gene therapies for blindness diseases, announced it will present its modifier gene therapy platform and clinical trial results at several investor and industry conferences in September 2026. The presentations aim to showcase the safety and efficacy of its OCU410 gene therapy for geograp…